Johnson & Johnson $(JNJ)$ shares rose 0.4% in premarket trades after the medical-technology and drug company beat Wall Street's profit and revenue estimates and raised its full-year sales guidance.
Johnson & Johnson reported per-share earnings of $4.54 for the quarter, which includes the reversal of special charges, up from $1.34 a share in the prior year's quarter.
Adjusted for one-time items, EPS came to $2.77 a share, above the $2.58 FactSet consensus.
Sales rose 2.4% to $21.893 billion, above the FactSet consensus of $21.559 billion. The New Brunswick, N.J.-based company raised its full-year operational sales guidance to a range of $91.6 billion to $92.4 billion, from its prior outlook of $90.9 billion to $91.7 billion. Johnson & Johnson said that this reflects the addition of the CAPLYTA medication for treating bi-polar depression following the completion of the Intra-Cellular Therapies acquisition.
In a separate announcement, Johnson & Johnson announced a 4.8% increase in its quarterly dividend, from $1.24 to $1.30 a share. The raised marked the 63rd year of consecutive dividend raises, the company said.
(This is a developing news story with updates to come.)
-James Rogers
For more from MarketWatch: http://www.marketwatch.com/newsviewer
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
April 15, 2025 06:48 ET (10:48 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。